New Study Indicates Benefits of Ampligen(r) in Treatment of Severe CFS

BRUSSELS, Belgium, Sept. 13 1999 PRNewswire

Hemispherx Biopharma, Inc. today announced results of an independent
evaluation of the potential pharmaco-economic benefits of Ampligen(R) in
treatment of severe CFS/ME, including a decrease in the number of doses of
other medicines used with Ampligen(R) and inpatient hospital treatment
days. 

The findings were presented at the Second World Conference on CFS in
Brussels and developed by EPI-Q, an independent company that conducts
pharmaco-economic studies under grand support. 

Subjects were randomized to receive 24 weeks of Ampligen(R) versus placebo
administered by intravenous infusion twice weekly. 

Independent data from Dr. Kenny De Meirleir et al also presented at the
Second World Conference on CFS indicate that the duration of Ampligen(R)
positive response remains constant for at least 42 months following
treatment initiation.

...twice-weekly infusion of Ampligen(R) as a treatment of CFS/ME can
reduce the utilization of health-care services and concomitant medications
resulting overall in more than 100% return on investment for insurance
carriers.

Web site: http://www.hemispherx.com/